Peimin Zhu, MD
Neurology · Shreveport, LANPI 1013174143
Payments from drug & device makers
Across 365 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$1K
- AstraZeneca$915
- UCB, Inc.$583
- Novartis$553
- Livanova USA, Inc.$433
- plus $4K from 29 others
What the payments were for
- Food & beverage$8,270100%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 85 | $1,014 |
| Amgen(2 entities) | 50 | $1,002 |
| AstraZeneca(2 entities) | 12 | $915 |
| UCB, Inc. | 18 | $583 |
| Novartis | 34 | $553 |
| Livanova USA, Inc. | 11 | $433 |
| SK Life Science, Inc. | 14 | $416 |
| Neurelis, Inc. | 17 | $410 |
| Sanofi | 13 | $372 |
| Argenx US, Inc. | 7 | $348 |
| Sunovion Pharmaceuticals Inc. | 24 | $296 |
| EMD Serono, Inc. | 6 | $204 |
| E.r. Squibb & Sons, L.L.C. | 2 | $201 |
| Lundbeck LLC | 4 | $186 |
| Pfizer | 13 | $185 |
| Greenwich Biosciences, Inc. | 10 | $166 |
| Medtronic | 1 | $125 |
| Avanir Pharmaceuticals, Inc. | 1 | $124 |
| Jazz Pharmaceuticals Inc. | 6 | $122 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $90 |
| Biogen | 5 | $85 |
| Acadia Pharmaceuticals Inc | 5 | $79 |
| Lilly USA, LLC | 4 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Eisai Inc. | 3 | $52 |
| Amneal Pharmaceuticals LLC | 2 | $38 |
| Neurocrine Biosciences, Inc. | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Merz Pharmaceuticals, LLC | 1 | $27 |
| Boston Scientific | 1 | $22 |
| Zogenix Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Averitas Pharma Inc. | 1 | $14 |
| Itamar Medical Inc | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,306 in reported general payments places this provider in the 65th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 24 | $718 |
Paid to pharmacies, not to this prescriber.
Other neurology in Shreveport
- Meghan HarrisShreveport$698K
- Erik BurtonShreveport$192K
- Ernest LittleShreveport$52K
- Chaitanya AmrutkarShreveport$17K
- Suresh KumarShreveport$16K
- Debra DavisShreveport$16K
- Jenny GuerreShreveport$15K
- Gurleen SikandShreveport$14K
- Ariel Antezana AntezanaAlexandria$2.5M
- Jon OlsonBaton Rouge$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.